Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Star Combo Pharma Ltd. ( (AU:S66) ) just unveiled an announcement.
Star Combo Pharma Ltd’s CEO Su Zhang presented at the 2025 Annual General Meeting, highlighting the company’s ongoing commitment to expanding its operations and maintaining strong relationships with business partners, customers, and employees. The presentation underscores the company’s strategic focus on growth within the health supplement industry, leveraging its established distribution networks and adherence to high manufacturing standards.
The most recent analyst rating on (AU:S66) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on Star Combo Pharma Ltd. stock, see the AU:S66 Stock Forecast page.
More about Star Combo Pharma Ltd.
Star Combo Pharma Ltd is a Sydney-based contract manufacturer specializing in vitamins, health, and beauty products, with a focus on natural ingredients and scientific research and development. The company distributes its products through the Australian pharmacy network and wholesale customers in Australia and China, aiming to be a leading manufacturer of premium vitamins and dietary supplements.
Average Trading Volume: 22,765
Technical Sentiment Signal: Buy
Current Market Cap: A$29.03M
See more insights into S66 stock on TipRanks’ Stock Analysis page.